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FACTORS ASSOCIATED WITH SUBOPTIMAL ADHERENCE TO HUMAN 
IMMUNODEFICIENCY VIRUS THERAPY
Snower KN, Lynn JB
CVS Caremark, Northbrook, IL, USA
OBJECTIVES: Adherence to medications is an integral component of treating human 
immunodeﬁciency virus (HIV). The objective of this study was to identify factors 
associated with suboptimal adherence to HIV therapy (MPR < 95%). METHODS: 
HIV patients were identiﬁed by a pharmacy claim between January 1, 2008 and 
November 30, 2008, for a non-nucleoside reverse transcriptase inhibitor, protease 
inhibitor, nucleoside reverse transcriptase inhibitor, entry inhibitor, integrase inhibitor 
or combination medication, using a large de-identiﬁed administrative claims database. 
Medication possession ratio (MPR) was calculated during the 12 months following 
their index prescription for those patients continuously enrolled and with at least two 
ﬁlls per medication. For patients utilizing more than one HIV medication, a mean 
MPR was calculated, weighted by length of time on each medication. Logistic regres-
sion was used to identify factors associated with suboptimal adherence. RESULTS: 
The analysis included 18,497 patients (20.0% female, mean age 46.7 years). Mean 
MPR was 87.2% (95% CI: 86.9–87.4), with 48.6% of patients having suboptimal 
adherence. Suboptimal adherence was associated with female gender (OR = 1.55, 95% 
CI: 1.44–1.68), dispenses from retail pharmacies (OR = 1.54, 95% CI: 1.43–1.67), 
less than three-months supply per dispense (OR = 1.38, 95% CI: 1.26–1.52), patient 
age less than 45 years (OR = 1.26, 95% CI: 1.18–1.34), using more than one pharmacy 
for HIV medications (OR = 1.20, 95% CI: 1.11–1.29), being new to therapy (OR = 
1.12, 95% CI: 1.04–1.19), taking more pills per day (OR = 1.09 for each additional 
pill per day, 95% CI: 1.06–1.12) and using more HIV medications (OR = 1.08 for 
each additional medication, 95% CI: 1.06–1.11). Type of insurance coverage and 
amount of copay were not signiﬁcantly associated with suboptimal adherence. CON-
CLUSIONS: Knowledge of factors related to suboptimal adherence can help identify 
HIV patients who may require additional attention during their course of care.
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FEASIBILITY STUDY OF A NOVEL METHOD TO QUANTIFY SURGICAL 
INTERVENTIONS IN PATIENTS WITH COMPLICATED SKIN AND SKIN 
STRUCTURE INFECTIONS (CSSSI) USING HOSPITAL ELECTRONIC 
HEALTH RECORD DATA
Emons MF1, Campbell RS1, Kothari S2, Fiske S1, Hays HD1, Zilberberg M3
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Astellas Pharma US, Deerﬁeld, IL, USA, 
3University of Massachusetts, Goshen, MA, USA
OBJECTIVES: cSSSI may be associated with signiﬁcant morbidity and cost. ICD-
9-CM diagnosis codes have been used to identify cSSSI in health care databases. 
Although early surgical interventions may provide important severity adjustment 
information, minor (bedside) surgical procedures may be under-reported in hospital 
data. We explored a novel method to identify surgical interventions using culture 
descriptions. METHODS: We conducted an analysis (April 2005-March 2009) of the 
Health Facts® database (Cerner Corp., Kansas City, MO), containing comprehensive 
clinical records from 115 US hospitals. We included all adult initial admissions with 
ICD-9-CM codes speciﬁc to cSSSI and with eligible positive cultures (from pre-deﬁned 
skin/soft tissue sources or from blood) within the ﬁrst 48 hours. In addition to using 
ICD-9-CM codes to identify procedures, we identiﬁed surgical interventions as “pre-
sumed” when a culture was from a source/site that would require a procedure to 
obtain (e.g., abscess, aspirate, excision site). Because Staphylococcus aureus (SA) may 
present as an abscess, to explore the face validity of our method we stratiﬁed the 
results by SA status, and the SA further by methicillin resistance (MRSA) vs. sensitivity 
(MSSA). RESULTS: Among 7,183 patients included, 22.5% had a procedure identi-
ﬁed by ICD-9-CM code, 24.6% had a presumed procedure, and 36.6% were identiﬁed 
by both criteria. Overall, cultures were positive for MRSA in 33%, MSSA in 26% 
and non-SA organisms in 41%. When both procedure criteria were applied, surgical 
intervention among those with MRSA, MSSA and non-SA isolates was 34.9%, 21.4% 
and 19%, respectively. CONCLUSIONS: Our novel method appears feasible and may 
provide a more complete accounting of surgical procedures in cSSSI hospitalizations, 
though it requires clinical validation. Notably, in this large cohort of hospitalized cSSSI 
patients, nearly 60% had cultures positive for SA.
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USE OF AN ELECTRONIC HEALTH RECORD (EHR) DATABASE TO 
IDENTIFY HOSPITAL-ACQUIRED PNEUMONIA (HAP)
Campbell RS1, Spoeri RK1, Harris AD2, Kothari S3, Fiske S1, Hays HD1, Emons MF1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2University of Maryland, Baltimore, MD, USA, 
3Astellas Pharma US, Deerﬁeld, IL, USA
OBJECTIVES: HAP confers signiﬁcant mortality, morbidity and cost. Observational 
studies using real-world data have been limited. We sought to develop a methodology 
to identify and characterize patients with HAP in a large multihospital database 
without reliance upon radiographs or reviewer designation of infection origin. 
METHODS: We conducted a retrospective analysis (2005–2008) of the Health Facts® 
database (Cerner Corp., Kansas City, MO), which contains comprehensive clinical 
records from 115 US hospitals. Adult patients with a secondary discharge diagnosis 
consistent with pneumonia and a positive respiratory or blood culture obtained >48 
hours after admission were included as HAP. Respiratory cultures were deﬁned by 
site/source and the ﬁrst positive culture was selected. Qualiﬁed blood cultures were 
used when there was no respiratory culture and no other infection. Hierarchical selec-
tion was used when multiple cultures were collected at the same time. Methicillin-
resistant- (MRSA) or methicillin-sensitive- Staphylococcus aureus (MSSA) status was 
designated based on antibiotic susceptibilities. RESULTS: A total of 3,041 patients 
met criteria for HAP; 434 (14.3%) had an index culture positive for MRSA and 598 
(19.9%) for MSSA. Most patients (94%) qualiﬁed with a respiratory culture. The 
cohort was predominantly male (61%) and Caucasian (80%); mean age was 64 years. 
Primary diagnoses were varied; the three most common were other diseases of lung 
(9%), acute myocardial infarction (3.8%), and lung cancer (3.8%). MRSA patients 
were older, with more comorbidities vs MSSA patients. More MSSA isolates were 
polymicrobial (41%) vs. MRSA (22.5%) and included Gram-negative organisms 
(33% vs. 19%). Data generated is illustrative of methodology. CONCLUSIONS: Our 
algorithm identifying HAP patients within an EHR dataset potentially allows for 
larger sample size than other studies using clinical records from a single institution. 
Chart review is crucial to validate our approach and further work is needed to 
compare this deﬁnition with National Healthcare Safety Network deﬁnition.
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APPLICATION OF A NATIONAL PRESCRIPTION DATABASE TO DEVISE 
A PREDICTIVE MODEL FOR TAILORING HIV/AIDS THERAPEUTIC 
MANAGEMENT
Garavaglia SB1, Khalid M1, Bruno M2, Nichols LA1, Kagan SA3, Castle L1, Aubert RE1
1Medco Health Services, Inc, Franklin Lakes, NJ, USA, 2Pﬁzer Inc., New York, NY, USA, 
3Pﬁzer Inc., Atlanta, GA, USA
OBJECTIVES: Design a predictive model which determines the probability of patients 
using a drug typically prescribed later in the therapeutic management of HIV/AIDS. 
Determining when a patient may need to switch to a different antiretroviral regimen 
for HIV/AIDS due to complexities (e.g., resistance, poor adherence, etc.) remains 
challenging. Personalized approaches for the therapeutic management of HIV/AIDS 
are needed. A national database of pharmacy claims was analyzed to develop a predic-
tive model that can be used with traditional measures for regimen selection. 
METHODS: Beginning April 2006 to March 2009, prescription claim data for 15,828 
patients with continuous beneﬁt eligibility were analyzed for; antiretroviral drug 
regimen, presence of co-morbid illnesses (across 50 diseases), and basic demographics. 
Regimen identiﬁcation was based on drug combinations included in the 2008 DHHS 
Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adoles-
cents. Late-type regimens included enfuvirtide, etravirine, maraviroc, or raltegravir. A 
multivariate logistic regression model was utilized across drug-centric and patient-
centric domains to analyze the likelihood of a patient being prescribed a late-type 
regimen. RESULTS: N = 15,828 patients initially included in the model and n = 1,838 
(11.6%) identiﬁed with a claim for the target drug(s). Five or more drug regimens 
(OR = 32.81; CI: 28.29–38.04) and three or more average number of drugs per 
regimen (OR = 4.13; CI: 3.15 − 4.87) are the strongest predictors and dominate the 
model. Cancer (OR = 1.80; CI: 1.31–2.32), type 2 diabetes (OR = 1.74; CI: 1.38–
2.20), acne (OR = 1.56; CI: 1.09−2.22), and Benign Prostate Hyperplasia (OR = 1.54; 
CI: 1.14–2.08) were also signiﬁcant. CONCLUSIONS: Ability to develop and apply 
a highly predictive model identifying patients suitable for drugs typically prescribed 
later in therapeutic management of HIV/AIDS exists. Application of this model can 
lend signiﬁcant insight into patient management and further therapeutic precision. 
Additional studies are needed to conﬁrm the clinical beneﬁt of this model.
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METHODS TO IDENTIFY AND COMPARE BLOODSTREAM INFECTION 
RATES AMONG PATIENTS ADMINISTERED PARENTERAL NUTRITION 
VIA HOSPITAL COMPOUNDED VS. PREMIXED MULTI-CHAMBER BAGS
Liu FX1, Mercaldi K2, Reynolds MW3, Turpin R1
1Baxter Healthcare Corporation, Deerﬁeld, IL, USA, 2United BioSource Corporation, 
Bethesda, MD, USA, 3United BioSource Corporation, Lexington, MA, USA
BACKGROUND: Parenteral, or intravenous nutrition (PN) is used with patients when 
oral or enteral nutrition isn’t possible or adequate. Though PN provides important 
therapeutic beneﬁts, it also is associated with a higher risk of infection. Yet few studies 
have compared bloodstream infection rates (BSI) among patients receiving PN through 
custom compound formulations (COM) with standardized premixed multi-chamber 
bags (MCB). Our objective was to develop a credible approach to exploring the rela-
tionship between PN type and BSI rates. METHODS: We examined the Premier Per-
spectiveTM database for adult patients (≥18 years) who received PN between 2005 and 
2007. Patients were identiﬁed as either COM or MCB by searching standardized PN-
related charge codes. BSI rates were identiﬁed via ICD-9 codes; sensitivity analyses 
utilized ICD-9 codes plus ≥1 billing charge for iv antibiotics. Chi-square and t-tests 
compared differences between MCB and COM PN. Logistic regression modeled BSI 
rates controlling for patient and hospital characteristics, as well as risk factors for 
infection. Propensity score modeling was used to validate logistic regression ﬁndings. 
RESULTS: Of over 11 million inpatients in the database, 68,984 adult patients received 
PN and met study inclusion criteria. Of these, 4,669 received PN via MCB and 64,315 
received COM PN. Univariate statistics indicated that COM PN patients may have 
been at higher risk for infection. Controlling for observable variables, multivariate 
logistic regression indicated that MCBs were associated with a lower risk of BSI (31%), 
compared to COM (35%); p < 0.0001. In our sensitivity analysis, infection rates identi-
ﬁed via ICD-9 codes were similar to rates based on ICD-9 codes plus iv antibiotics. 
Propensity score modeling validated our logistic regression ﬁndings. CONCLUSIONS: 
